A novel endosome-escaping, macrophage-targeted nanoparticle platform for miR-146a delivery with favorable in vivo biodistribution and biocompatibility

This study presents a novel, biocompatible, mannose-functionalized lipid nanoparticle platform that efficiently delivers anti-inflammatory miR-146a to macrophages with enhanced endosomal escape and favorable in vivo biodistribution, offering a promising therapeutic strategy for treating macrophage-driven inflammatory disorders.

The Gist

Imagine your body's immune system as a bustling city. Sometimes, after an injury or when a medical implant (like a pacemaker or artificial joint) is put in, the city's security guards (macrophages) get a little too excited. They start building walls and barricades around the "invader," causing inflammation and scarring. This is called a "foreign body response," and it can ruin the function of the implant.

The scientists in this paper wanted to calm these overzealous guards down. They discovered a specific "peacekeeper" molecule called miR-146a that naturally tells the guards to stand down. However, there's a problem: if you just drop this molecule into the body, it gets eaten by enzymes immediately, like a sugar cube dissolving in hot tea. It never reaches the guards.

So, the team built a high-tech delivery truck to get the peacekeeper to the right place. Here is how they did it, explained simply:

1. The Truck: A Smart Lipid Nanoparticle

Think of the nanoparticle as a tiny, microscopic bubble made of fat (lipids). It's designed to carry the fragile miR-146a message safely through the bloodstream.

• The Shield: The bubble is tough. It can survive the acidic stomach of a cell (the endosome) and the harsh environment of the blood without breaking apart.
• The Engine: They used a special mix of four ingredients. One ingredient acts like a "key" to unlock the cell door, another helps the bubble burst open once inside to release the cargo, and a third keeps the bubble stable.

2. The GPS: The Mannose "Address Label"

This is the coolest part. The scientists didn't just want the truck to go anywhere; they wanted it to go specifically to the macrophages (the security guards).

• They attached a mannose tag to the outside of the truck.
• Think of macrophages as having a specific mailbox that only accepts letters with a "Mannose" stamp.
• When the truck arrives, the macrophage sees the stamp, grabs the truck, and pulls it inside. This is called targeted delivery. Without this tag, the truck would just bounce off the cell or get lost.

3. The Escape Artist: Getting Out of the Trap

Once the cell grabs the truck, it usually puts it in a little cage (a lysosome) to digest it. If the truck stays there, the message is destroyed.

• This new truck is designed to be an escape artist. Once inside the cage, it changes shape and bursts out, releasing the miR-146a into the main room of the cell (the cytoplasm) where it can do its job.
• The paper showed that this truck escapes the cage much faster and more efficiently than standard trucks.

4. The Results: A Calm City

When they tested this on mice:

• Safety: The trucks were completely safe. They didn't hurt the liver, kidneys, or blood cells. It was like sending a gentle breeze through the city, not a storm.
• Delivery: The trucks went exactly where they were supposed to. When injected under the skin, they stayed right there, calming the local inflammation. When injected into the blood, they traveled to the heart and blood vessels (where inflammation often happens) without clogging up other organs.
• Effectiveness: Inside the cells, the miR-146a message was delivered successfully. It turned down the volume on the inflammatory signals, effectively telling the security guards to stop building barricades.

Why Does This Matter?

Currently, if you get a medical implant, your body might reject it because of this inflammation. This new technology offers a way to trick the body into accepting the implant by delivering a "calm down" signal directly to the cells causing the trouble.

In a nutshell: The scientists built a smart, unbreakable, GPS-guided bubble that carries a "peace treaty" message directly to the immune cells that cause scarring. It's safe, it works fast, and it stays exactly where it's needed, offering a promising new way to help medical implants work better and last longer.

Technical Summary

1. Problem Statement

Therapeutic application of microRNAs (miRs), specifically miR-146a (a potent anti-inflammatory regulator), is hindered by several critical barriers:

• Instability: Rapid degradation by nucleases in circulation and poor stability in biological fluids.
• Delivery Efficiency: Suboptimal cytosolic delivery due to entrapment in endosomes/lysosomes and lack of cell-specific targeting.
• Inflammatory Pathologies: There is a need for targeted therapies to modulate macrophage-driven inflammation, particularly in biomaterial-associated foreign body responses (FBR), fibrosis, and chronic inflammatory diseases. Existing lipid nanoparticle (LNP) systems often lack specific targeting capabilities or sufficient endosomal escape mechanisms for miR delivery.

2. Methodology

The authors engineered a novel Macrophage-targeted Lipid Nanoparticle (MacLNP) system designed to encapsulate and deliver miR-146a.

• Formulation Strategy:

  • Lipid Composition: A four-lipid system with a molar ratio of 40:10:48:2 (DOPE:DOTAP:Linoleic Acid (LA):PA-PEG3-Mannose).
    • DOTAP: Cationic lipid for electrostatic complexation with negatively charged miR.
    • DOPE & LA: Fusogenic helper lipids to promote membrane destabilization and endosomal escape.
    • PA-PEG3-Mannose: Targeting ligand for the Mannose Receptor (CD206) on macrophages; also provides colloidal stability.
  • Fabrication: Utilized a scalable ethanolic injection method combined with vigorous stirring and sonication.
  • Loading: miR-146a was complexed with Polyethyleneimine (PEI) at varying N/P ratios before being loaded into the lipid nanoparticles. The 1:10 N/P ratio was identified as optimal for encapsulation efficiency and stability.

• Characterization & Testing:

  • Physicochemical: Dynamic Light Scattering (DLS) for size/PDI, Zeta potential, and Transmission Electron Microscopy (TEM) for morphology.
  • Stability: Assessed under varying pH (2.5–10.0), serum conditions (1% and 10% FBS), and storage (4°C) using agarose gel electrophoresis.
  • In Vitro: Primary mouse peritoneal macrophages (MPMs) and bone marrow-derived macrophages (BMDMs) were used to test cytotoxicity (MTT, Live/Dead), cellular uptake (NBD-PE and Cy3 labeling), receptor-mediated uptake (mannose competition), and endosomal escape (LysoTracker colocalization).
  • In Vivo: C57BL/6 and ApoE-/- mice were used to evaluate systemic biodistribution (IVIS imaging), subcutaneous retention, and biocompatibility (hepatic/renal function markers, hematology).

3. Key Contributions

• Rational Design: Developed a specific 4-lipid formulation that balances charge, stability, and targeting, overcoming the limitations of standard LNPs.
• Targeted Delivery: Successfully engineered a system that specifically targets macrophages via the CD206 mannose receptor, validated by competitive inhibition assays.
• Endosomal Escape Mechanism: Demonstrated that the inclusion of DOPE and Linoleic Acid facilitates efficient escape from lysosomes, a critical bottleneck for miR therapeutics.
• Scalable Manufacturing: Established a robust, scalable lipid-injection protocol that yields uniform nanoparticles with high encapsulation efficiency (~92–95%).

4. Key Results

• Physicochemical Properties:

  • MacLNP12 (12 mol% mannose) exhibited a hydrodynamic diameter of ~151 nm and a low Polydispersity Index (PDI).
  • Encapsulation of miR-146a shifted the zeta potential from negative to near-neutral (approx. -5 mV), confirming successful complexation.
  • Stability: MacLNP12-miR146a remained stable at 4°C for 14 days and resisted degradation in 10% serum. It showed stability across pH 2.5–8.0, with destabilization only occurring at highly alkaline pH (10) or prolonged acidic exposure (24h at pH 2.5).

• In Vitro Performance:

  • Biocompatibility: No significant cytotoxicity observed in primary macrophages up to 50 µg/ml (viability >75%).
  • Uptake: MacLNP12 showed significantly higher uptake in macrophages compared to non-targeted LNPs. Uptake was CD206-dependent, as free mannose competitively inhibited internalization.
  • Functional Delivery: MacLNP12-miR146a increased intracellular miR-146a levels by ~5-fold compared to non-targeted LNPs. This led to a ~30% reduction in TRAF6 (a validated miR-146a target), confirming functional gene silencing.
  • Endosomal Escape: Confocal microscopy showed a 70% reduction in lysosomal colocalization by 24 hours, indicating successful escape into the cytosol.

• In Vivo Performance:

  • Biodistribution:
    • Subcutaneous: Showed durable retention at the injection site with minimal systemic spread over 7 days.
    • Intravenous: In ApoE-/- mice, nanoparticles accumulated preferentially in the aortic arch and abdominal aorta (sites of inflammation/atherosclerosis) and the liver (clearance), with minimal accumulation in the heart, lungs, or kidneys.
  • Safety: Comprehensive analysis of liver enzymes (AST, ALT), kidney function (BUN, Creatinine), metabolic electrolytes, and hematological parameters revealed no toxicity in mice treated with MacLNP12 or MacLNP12-miR146a compared to controls.

5. Significance

This study presents a translational nanotherapeutic platform that addresses the major hurdles of miRNA delivery:

1. Clinical Relevance: By targeting macrophages and delivering miR-146a, this platform offers a promising strategy to treat biomaterial-associated inflammation, chronic wounds, and inflammatory diseases (e.g., atherosclerosis) where macrophage dysregulation is central.
2. Safety Profile: The demonstrated lack of systemic toxicity and favorable biodistribution profile suggests the platform is safe for potential clinical application.
3. Mechanistic Insight: The work validates that combining fusogenic lipids (DOPE/LA) with specific targeting ligands (Mannose) creates a synergistic effect, enabling efficient endosomal escape and cytosolic delivery of therapeutic nucleic acids.

The authors conclude that MacLNP-miR146a is a robust, scalable, and biocompatible system capable of modulating macrophage-driven inflammation, paving the way for future clinical trials in treating inflammatory and fibrotic pathologies.